Compounders Research Compare

Viridian Therapeutics, Inc.(VRDN)

Biotechnology · Waltham, MA

$18.22-0.78 (-4.11%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

Waltham, MA

252 employees

www.viridiantherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Stephen F. Mahoney

View full financials

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T22:04:41.746Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:04:41.746Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 2,064,180,240
TTM free cash flow · period ending 2026-06-30: -335,039,000

FMP input reference: b864e21534e19d3622fdd1df0bfa06a86802ee3b4002ae0b13a65066f94ec11b

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

VRDN Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

VRDN Competitors' Price/FCF Ratio

Viridian Therapeutics, Inc.

Current

Market Cap

$2.06B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Celldex Therapeutics, Inc.

Market Cap

$2.06B

Price/FCF Ratio

N/A

TTM Avg

9.03

3Y Avg

8.56

5Y Avg

8.56

Alvotech

Market Cap

$2.08B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Vericel Corporation

Market Cap

$2.05B

Price/FCF Ratio

41.31

TTM Avg

42.75

3Y Avg

385.34

5Y Avg

202.04

Progyny, Inc.

Market Cap

$2.03B

Price/FCF Ratio

9.31

TTM Avg

10.72

3Y Avg

12.71

5Y Avg

64.86

BioCryst Pharmaceuticals, Inc.

Market Cap

$2.02B

Price/FCF Ratio

5.66

TTM Avg

22.88

3Y Avg

35.76

5Y Avg

35.76

SELLAS Life Sciences Group, Inc.

Market Cap

$2.11B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

UroGen Pharma Ltd.

Market Cap

$2.02B

Price/FCF Ratio

N/A

TTM Avg

57.21

3Y Avg

57.21

5Y Avg

57.21

Aurinia Pharmaceuticals Inc.

Market Cap

$2.02B

Price/FCF Ratio

11.62

TTM Avg

15.26

3Y Avg

21.56

5Y Avg

21.56

Vera Therapeutics, Inc.

Market Cap

$2.11B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Viridian Therapeutics, Inc. (VRDN)	$2.06B	N/A	N/A	N/A	N/A
Celldex Therapeutics, Inc. (CLDX)vs ›	$2.06B	N/A	9.03	8.56	8.56
Alvotech (ALVO)vs ›	$2.08B	N/A	N/A	N/A	N/A
Vericel Corporation (VCEL)vs ›	$2.05B	41.31	42.75	385.34	202.04
Progyny, Inc. (PGNY)vs ›	$2.03B	9.31	10.72	12.71	64.86
BioCryst Pharmaceuticals, Inc. (BCRX)vs ›	$2.02B	5.66	22.88	35.76	35.76
SELLAS Life Sciences Group, Inc. (SLS)vs ›	$2.11B	N/A	N/A	N/A	N/A
UroGen Pharma Ltd. (URGN)vs ›	$2.02B	N/A	57.21	57.21	57.21
Aurinia Pharmaceuticals Inc. (AUPH)vs ›	$2.02B	11.62	15.26	21.56	21.56
Vera Therapeutics, Inc. (VERA)vs ›	$2.11B	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Growth Operating Margin All Metrics